Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis

by NASDAQ Market News January 14, 2021

NASDAQ Market News
Click here to email author

Teladoc Health Issues Inaugural Corporate Social Responsibility Report

Medical Device Testing Market to Reach $12.5 Billion by 2027, Growing at a CAGR of 4.7% From 2020 With COVID-19 Impact – Meticulous Research® Analysis

Ads